Drugs / [68Ga]Ga-DWJ155
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07117214 | Jun 2026 → Dec 2028 expected | breast neoplasm, non-small cell lung carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-DWJ155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07117214 ↗ |
| Known as | FKL480 | “Patients will receive FKL480 (\[68Ga\]Ga-DWJ155)” NCT07117214 ↗ |
| Modality | Diagnostic / imaging agent | “Radioligand imaging agent” NCT07117214 ↗ |